WVE - Wave Life Sciences Ltd.
37.60 0.00 (0.00%)
After hours: 4:42PM EST
| Previous Close | 36.53 |
| Open | 36.87 |
| Bid | 30.20 x 1000 |
| Ask | 40.00 x 800 |
| Day's Range | 36.78 - 37.61 |
| 52 Week Range | 32.25 - 56.00 |
| Volume | 197,248 |
| Avg. Volume | 295,063 |
| Market Cap | 1.256B |
| Beta (3Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.89 |
| Earnings Date | Aug 14, 2017 - Aug 18, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 60.57 |
- PR Newswire•3 days ago
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs ...
- Simply Wall St.•17 days ago
Why Wave Life Sciences Ltd.’s (NASDAQ:WVE) CEO Pay Matters To You
Paul Bolno has been the CEO of Wave Life Sciences Ltd. (NASDAQ:WVE) since 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies Read More...
- American City Business Journals•17 days ago
New life science internship program launches to help boost diversity
In the inaugural year of Project Onramp, 50 low-income students will be placed in paid science, engineering, communication, marketing and other internships with local biotech and medical device companies, according to the announcement made Tuesday.
- Motley Fool•22 days ago
Here's Why Wave Life Sciences Is Crashing Today
Investors aren't too thrilled about this biotech's latest share offering.
- GlobeNewswire•22 days ago
Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares
Wave Life Sciences Ltd. (WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten public offering of 3,950,000 of its ordinary shares at a price to the public of $38.00 per ordinary share. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 592,500 of its ordinary shares on the same terms and conditions.
- GlobeNewswire•23 days ago
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares
Wave Life Sciences Ltd. (WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of its ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the public offering on the same terms and conditions. All of the shares in the offering will be sold by Wave Life Sciences.
- American City Business Journals•last month
FDA pilot program could help Wave avoid orphan-drug pitfalls
Wave will work with FDA officials during the pilot program to design a Phase 2-3 clinical trial with a reduced number of placebo patients, tweaking standards that have stymied other rare disease products.
- Motley Fool•last month
Here's Why Sarepta Therapeutics Fell 15.7% in December
A competitive threat is advancing, but investors might want to view last month's pullback as an opportunity.
- GlobeNewswire•last month
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program
Wave Life Sciences Ltd. (WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the planned Phase 2/3 efficacy and safety trial for its lead Duchenne muscular dystrophy (DMD) clinical program has been selected for the U.S. Food and Drug Administration (FDA) pilot program for complex innovative trial designs (CID). The selection was based on the design of Wave’s Phase 2/3 clinical trial of suvodirsen (WVE-210201), an investigational therapy for boys with DMD who are amenable to exon 51 skipping.
- Simply Wall St.•2 months ago
How Financially Strong Is Wave Life Sciences Ltd. (NASDAQ:WVE)?
The direct benefit for Wave Life Sciences Ltd. (NASDAQ:WVE), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the Read More...
- GlobeNewswire•2 months ago
Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)
Wave Life Sciences Ltd. (WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the safety and tolerability data from the WVE-210201 Phase 1 clinical trial in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping support initiation of a Phase 2/3 clinical trial. Based on results from four ascending dose cohorts in the Phase 1 trial and pending final analysis, Wave has selected a dose for its planned Phase 2/3 clinical trial of WVE-210201, which it intends to initiate in 2019.
- Benzinga•3 months ago
Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'
With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week. The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...
- Zacks•3 months ago
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.40% and -16.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Wave Life Sciences: 3Q Earnings Snapshot
The Singapore-based company said it had a loss of $1.28 per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
- Simply Wall St.•4 months ago
Should You Be Holding Wave Life Sciences Ltd (NASDAQ:WVE) Right Now?
Anyone researching Wave Life Sciences Ltd (NASDAQ:WVE) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and Read More...
- Zacks•6 months ago
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.82% and -33.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•6 months ago
Wave Life Sciences: 2Q Earnings Snapshot
The Singapore-based company said it had a loss of $1.23 per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...
